Gupta and Mohan

Robichaud AJ 2006 Approaches to Palliative Therapies for Alzheimers Disease. Curr Top

Med Chem., 6 :553-568.

Schulz MN, Hubbard RE 2009 Recent progress in fragment-based lead discovery. Curr

Opin Pharmacol., 9 :615-621.

Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I 1991 Atomic

structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-

binding protein. Science., 253: 872-879.

The software package SYLVIA, Molecular Networks GmbH, Erlangen, Germany ( http://

www.molecularnetworks.com).

Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD 2003 Improved protein–

ligand docking using GOLD. Proteins: Struct, Funct, Bioinf., 52 :609-623.

Wang R, Gao Y, Lai L 2000 LigBuilder: a multi-purpose program for structure-based drug

design. J Mol Model., 6 :498-516.

Xie Q, Wang H, Xia Z, Lu M, Zhang W, Wang X, Fu W, Tang Y, Sheng W, Li W 2008 Bis-

(-)-nor-meptazinols as Novel Nanomolar Cholinesterase Inhibitors with High Inhibitory

Potency on Amyloid- Aggregation. J Med Chem., 51 :2027-2036.

Yu H, Li WM, Kan KKW, Ho JMK, Carlier PR, Pang YP, Gu ZM, Zhong Z, Chan K,

Wang YT 2008 The physicochemical properties and the in vivo AChE inhibition of

two potential anti-Alzheimer agents, bis (12)-hupyridone and bis (7)-tacrine. J Pharm

Biomed Anal., 46 :75-81.

Zartler ER, Shapiro MJ 2005 Fragonomics: fragment-based drug discovery. Curr Opin

Chem Biol., 9 :366-370.

126

Int. J. Bioinformatics and Biological Sci.: v.2 n.1&2, p. 111-126. March & June 2014